Another oral GLP-1 has posted phase 2b results, and once again there is nothing for this desk to price [1]. Aleniglipron is a small molecule taken once daily, escalated every four weeks, and tested in 230 adults whose average BMI was 39.5. It joins the list this desk already keeps in the eight-arm tablet trial.
Placebo-adjusted weight change at week 36 was 8.2% at 45 mg, 9.8% at 90 mg and 11.3% at 120 mg. Note the phrasing: these are placebo-adjusted, which means the placebo arm’s own change has already been subtracted. The figure a marketing page would print is the arm change, which is larger and which this abstract does not give.
On tolerability, treatment-related discontinuations ran 10.4% across the aleniglipron arms. Gastrointestinal events were generally mild to moderate and became less frequent over time, and the authors specifically note little or no recurrence of vomiting when the drug was reintroduced after a permitted interruption. No drug-induced liver injury occurred, which matters in this class because another oral molecule was stopped for liver enzymes, covered in the trial that was halted.
The authors also report no apparent weight-loss plateau by the end of the double-blind period, and continued weight loss at an interim look at the open-label extension, where the median treatment duration was 20 weeks. That is their description of a curve still moving, not a projection of where it ends. Anyone quoting a final number from it is inventing one.
For a buyer, the practical takeaway is unchanged from every other pipeline readout on this desk. The tablet that exists and is sold today is oral semaglutide, and its economics are set out in what the tablet actually costs. Everything else in the oral column is a press release with a confidence interval attached.